DRRX vs. SPRB, CASI, DARE, ENLV, JAN, THTX, APRE, FBIO, VIRX, and FBRX
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Spruce Biosciences (SPRB), CASI Pharmaceuticals (CASI), Daré Bioscience (DARE), Enlivex Therapeutics (ENLV), JanOne (JAN), Theratechnologies (THTX), Aprea Therapeutics (APRE), Fortress Biotech (FBIO), Viracta Therapeutics (VIRX), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical preparations" industry.
Spruce Biosciences (NASDAQ:SPRB) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.
Spruce Biosciences has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
DURECT received 278 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 65.83% of users gave DURECT an outperform vote while only 64.41% of users gave Spruce Biosciences an outperform vote.
91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by insiders. Comparatively, 4.3% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Spruce Biosciences currently has a consensus price target of $5.67, suggesting a potential upside of 661.24%. DURECT has a consensus price target of $27.50, suggesting a potential upside of 2,270.69%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe DURECT is more favorable than Spruce Biosciences.
DURECT has a net margin of -323.16% compared to DURECT's net margin of -474.96%. DURECT's return on equity of -52.31% beat Spruce Biosciences' return on equity.
DURECT has lower revenue, but higher earnings than Spruce Biosciences. DURECT is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, DURECT had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for DURECT and 1 mentions for Spruce Biosciences. DURECT's average media sentiment score of 0.53 beat Spruce Biosciences' score of 0.33 indicating that Spruce Biosciences is being referred to more favorably in the media.
Summary
DURECT beats Spruce Biosciences on 10 of the 18 factors compared between the two stocks.
Get DURECT News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
